Who is sponsoring NCT03553459?

NCT03553459 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03553459?

Interventions in NCT03553459: Trendelenburg Maneuver.

What condition does NCT03553459 study?

NCT03553459 studies Extracorporeal Membrane Oxygenation.

Is NCT03553459 still recruiting?

NCT03553459 is currently status unknown. Last updated 8 October 2019.

Last reviewed 2019-10-08 · How we verify

NCT03553459

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trendelenburg Maneuver Predicts Fluid Responsiveness in Patients With Extracorporeal Membrane Oxygenation (TEMPLE)

Status unknown NA Last updated 8 October 2019

What this trial tests

NA trial testing Trendelenburg Maneuver in Extracorporeal Membrane Oxygenation in 40 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
30 December 2022

30 December 2022

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 July 2018
Primary completion	30 December 2022
Estimated completion	30 December 2022
Sites	1 location across China

Drugs / interventions tested

Trendelenburg Maneuver

Conditions studied

Extracorporeal Membrane Oxygenation — all drugs for Extracorporeal Membrane Oxygenation →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 80, any sex, with Extracorporeal Membrane Oxygenation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to verify the efficacy of using trendelenburg maneuver to predict fluid responsiveness in patients with extracorporeal membrane oxygenation

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hemodynamic monitoring in patients with venoarterial extracorporeal membrane oxygenation.
Su Y, Liu K, Zheng JL, Li X, et al · · 2020 · cited 46× · PMID 32647717 · DOI 10.21037/atm.2020.03.186
Trendelenburg maneuver predicts fluid responsiveness in patients on veno-arterial extracorporeal membrane oxygenation.
Luo JC, Su Y, Dong LL, Hou JY, et al · · 2021 · cited 18× · PMID 33496906 · DOI 10.1186/s13613-021-00811-x

Verify or expand the search:

Other recruiting trials for Extracorporeal Membrane Oxygenation

Currently open trials in the same condition.

NCT06862700 — Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients · recruiting
NCT06560164 — Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO · NA · recruiting
NCT06369584 — Prone Position During ECMO in Pediatric Patients With Severe ARDS · NA · recruiting
NCT05574296 — Hydrogen's Feasibility and Safety as a Therapy in ECPR · Phase 1 · recruiting
NCT06660784 — Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance · active not recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03553459 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 8 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03553459.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing